-

Unilever plc Investor News: Robbins LLP is Investigating Unilever plc (UL) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Unilever plc (NYSE: UL) to determine whether they breached their fiduciary duties or violated securities laws by failing to disclose the Company's resolution to end sales of Ben & Jerry's ice cream in "Occupied Palestinian Territory." Unilever is one of the world's largest consumer goods companies.

If you would like more information about our investigation of Unilever plc's misconduct, click here.

What is this Case About: According to the class action complaint filed against Unilever, in 2000, Ben & Jerry's sold the company to Unilever for $326 million. In July 2020, Ben & Jerry's independent board passed a resolution to end sales of Ben & Jerry's products in areas that the Ben & Jerry's Board considers to be Palestinian territories illegally occupied by Israel. However, Ben & Jerry's CEO did not "operationalize" the resolution immediately.

On July 19, 2021, Unilever "operationalized" the Ben & Jerry's Board's resolution to boycott Israel. On that day, Ben & Jerry's announced that, upon the expiration of the current licensing agreement by which its products had been distributed in Israel for decades, it would end sales of its ice cream in "Occupied Palestinian Territory" but purportedly continue to sell its products in Israel. However, in a separate response reported by NBC News, the Ben & Jerry's Board disputed that Ben & Jerry's would remain in Israel and that Unilever had any authority to make such a promise.

The class action alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that in July 2020, Ben & Jerry’s board passed a resolution to end sales of its ice cream in “Occupied Palestinian Territory” as well as the risks attendant to the board’s decision. Additionally, Unilever’s description of its legal risks was materially false and misleading because Unilever acknowledged that complying with all applicable laws and regulations was important but omitted discussing Ben & Jerry’s boycott decision, which risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states (“Anti-BDS Legislation”).

In response to the boycott, Texas and Florida announced it was examining Ben & Jerry's action in connection with the states' Anti-BDS Legislation, with Florida's CFO stating in a letter to Ben & Jerry's CEO that refusal to do business in Israel will result in Ben & Jerry's being placed on the Scrutinized Companies that Boycott Israel list and that Florida would then be prohibited from investing in Ben & Jerry's or Unilever. On this news, the price of Unilever ADRs closed down over 5%.

Ultimately, the states of New York, New Jersey, Florida, Texas, Illinois, Colorado, and Arizona announced decisions to divest their pension fund investments in Unilever due to violations of their Anti-BDS Legislation.

Next Steps: If you acquired your shares of Unilever plc ADRs between September 2, 2020 and July 21, 2021, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Unilever plc settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:UL

Release Summary
Robbins LLP is investigating Unilever plc in connection to its decision to end sales of Ben & Jerry's ice cream in "Occupied Palestinian Territory."
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom